# Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

> **NCT06648889** · PHASE2 · RECRUITING · sponsor: **Goethe University** · enrollment: 40 (estimated)

## Conditions studied

- T-ALL

## Interventions

- **DRUG:** Isatuximab
- **DRUG:** Isatuximab

## Key facts

- **NCT ID:** NCT06648889
- **Lead sponsor:** Goethe University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-22
- **Primary completion:** 2028-02
- **Final completion:** 2028-08
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06648889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06648889, "Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06648889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*